Monitoring of therapy in patients with HIV/HCV co-infection who receive antiviral therapy against hepatitis C and antiretroviral therapy

L.R. Shostakovych-Koretskaya, О.P. Shevchenko-Makarenko, I.V. Chuhalova, O.V. Nosenko


The article presents data on the treatment of 90 patients with HIV/HCV (human immunodeficiency virus/hepatitis С virus) co-infection who received antiviral treatment against chronic viral hepatitis C (HVHC). Treatment using peginterferon in combination with direct acting drugs such as sofosbuvir and ribavirin was administered to 53 (59 %) patients on the background of antiretroviral therapy (ART), and other patients received non-interferon therapy. As a result of therapy monitoring, it has been found that some interferon- or ribavirin-dependent side effects occurred that required multi-disciplinary approach to patients’ management for timely correction of adverse events associated with both treatment regimen in HVHC and drug interactions in ART. Sustained virologic response (SVR12) was obtained in 86 (96.6 %) patients.


HIV/HCV co-infection; antiviral therapy; antiretroviral therapy

Copyright (c) 2018 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта